How To Conduct A Clinical Trial In Brazil
|
|
- Vanessa Ball
- 3 years ago
- Views:
Transcription
1 Sonia Mansoldo Dainesi, MD, PhD, MBA Post-trial access to trial drugs: Legal, ethical and practical issues Brocher Founda-on, Geneva Dec th, 2011
2 Poten-al conflicts of interest São Paulo University / Medical School (HCFMUSP) Specialization: Endocrinology PhD: Public Health Pharma companies: Rhodia Farma Sandoz Aventis Boehringer Ingelheim (currently Medical Director) Former president of SBMF (Braz Soc of Pharmaceutical Medicine) University ( ): Clinical Research Support Center (HCFMUSP) Brazilian Network of Clinical Research (Ministry of Health)
3 Background Local legislation E- Survey on post- trial access in Brazil Final considerations
4 Background Continuous growing of Brazil participation in international clinical trials (as well as other developing countries) BR: Strong history in ethics, mainly in biomedical research National Ethics Commission on Research (CONEP) as second ethics approval of protocols, after the EC/IRB approval Thiers F et al. Trends in the globalization of clinical trials. Nature Reviews. Drug Discovery 2008; 7:13-4. CONEP:
5 Legisla-on Resolutions from National Council of Health (CNS, Conselho Nacional de Saude) Res. 196/1996 Res. 251/1997 Res. 404/2008 Current options Res. ANVISA 26/1999: Expanded Access (EAP) Study Extension Donation Program
6 Res. CNS 196/96 (general principleson biomedical research) III.3m: Assure that, whenever possible, the research in communities is translated into benefits whose effects continue to be present after the research is concluded III.3n: Research involving human beings shall comply with the following: guarantee the benefits of the research to the people and communities where research is carried out.
7 Res. CNS 196/96 III.3p: Research involving human subjects must ensure to research subjects the benefits resulting from the research project, be it in terms of social return, access to procedures, products or research agents.
8 Res. CNS 251/97 (new drugs) IV.1m: access to the medicine being tested must be assured by the sponsor or by the institution, researcher, or promoter in the event its superiority to the conventional treatment is proven.
9 Res. CNS 404/08 (DoH modificagons not accepted)...all research participants should be assured the access to the best methods identified by the study... DoH
10 OpGons currently available in Brazil 1) ResoluGon 26 (1999) - ANVISA: Expanded Access (EAP) hvp:// 2) Study extension (Follow- up study) hvp:// hvp://conselho.saude.gov.br/biblioteca/livros/manual_ceps.pdf 3) DonaGon program hvp:// Or other clinical trial.
11 Law 6360 RDC 26/1999: Expanded Access Follow- up study Donation of study medication New product Not approved in the country Severe and life- threatening conditions Lack of therapeutic satisfactory options Protocol, CRF, Informed Consent Patients who benefit from treatment: optional continuity of treatment will be provided EC approval (and CONEP) together with the mother protocol Defined before the study initiation ANVISA recommends: Final report of the trial Medical report with the reasons for the donation Sponsor declaration: provide medication and continuous safety assessment
12 Since Multicenter International Clinical Trials If access to study medication after trial is not clearly stated in the protocols and informed consents, the trial is not approved by CONEP.
13
14 I. Identify the main issues on the continuity of study medication after trial end; II. Analyse the perspective of main players in clinical research on the topic.
15 Survey, with questionnaires sent through the internet ( ) Participants : 1. Clinical investigators (HIV/AIDS and DM) Identified through sponsors and 2. Members of ECs (Ethics Committees) As available at CONEP site (Feb 2009) 3. Sponsors Pharma companies and CROs established in Brazil 4. Research participants (patients) Questionnaires (paper & pen) through the clinical investigators
16 Mat & Met a) Non- probabilistic approach (convenience sample) b) Questionnaires Based in literature and adapted to current scenario (i) (ii) Three models: Clinical investigators Sponsors and EC members (iii) Research participants
17 Mat & Met c) Pilot assessment of questionnaires 2 lawyers with experience in clinical trials 2 members of ECs 2 clinical investigators 4 sponsors 1 assistant (lay people in research) Four domains: (i) Participants characteristics (ii) Informed consent (iii) Motivation (iv) Post-trial supply of study medication
18 Mat & Met Informed consent Questionnaire 3 weeks Mailing lists
19 Mat & Met EC (IRB) approval (Apr 2009; Aug 2009)
20 Sta-s-cal Analysis Data base Data base construction EpiData version 3.0 (2003) Validation Double entry, with validation Analysis Analysis: descriptive and non- inferential Absolute and relative frequency Significance level: 5% * Likert scale: Kruskal- Wallis test and, if necessary, non- parametric multiple comparisons * Non- Likert: Association (chi- square test or likelihood ratio test) * Verification inside each question: Friedman test, followed by non- parametric comparisons if necessary.
21 First Domain: Participants characteristiscs
22 Response Rate Questionnaires sent Questionnaires received Response Rate ECs ,7% Clinical investigators ,o% Sponsors ,3% Research participants NA (60-67% of responses arrived after first message)
23 Age and sex distribu-on Number of respondents Age (mean; range) ECs Sponsors Clinical Investigators Research participants (28-74) 40 (29-65) 53 (24-72) 49 (30-81) Sex Male (%) 54 (44,6%) 9 (37,5%) 37 (63,8%) 28 (51,9%) Female (%) 67 (55,4%) 15 (62,5%) 21 (36,2%) 26 (48,1%)
24 DistribuiGon by sex Research participants Clinical investigators Sponsors EC members Male Female
25 Distribu-on according to the schooling Fundamental (4 years) High school (8 years) EC Sponsors Clinical Investigators Research Participants (47,2%) 2 (1,7%) (28,3%) University 5 (3,4%) 5 (20,8%) 1 (1,7%) 12 (22,6%) Especialization 15 (12,7%) 6 (25%) 6 (10,3%) 0 Master 39 (33,1%) 5 (20,8%) 13 (22,4%) 1 (1,9%) PhD 54 (45,8%) 6 (25%) 30 (51,7%) 0 Other 3 (2,5%) 2 (8,3 %) 8 (13,8%) 0 Total 118 (100%) 24 (100%) 58 (100%) 53 (100%)
26 Distribu-on of par-cipants according to the region in Brazil EC Sponsors Others: 57% Southeast: 43% Others: 21% Sponsors and Research Participants: 80% Southeast EC and Clinical Investigators: 43% Southeast Clinical investigators Southeast: 43% Others: 19% Southeast: 79% Research participants Others: 57% Southeast: 81%
27 Second Domain: Attitudes regarding to Informed Consent process
28 How well informed are the research pargcipants? Less informed item (all groups together)
29 Which is the importance of each informa-on in the Informed Consent? Importance of Research Participants group gives to each aspect in the IC EC Clin Invest Sponsors Res Partic Importance of each group interviewed gives to the potential risks in the IC Research objective Potential benefits Potential risks Study design was the less important info for all groups
30 Third Domain: Decision factors and motivation for patients and investigators
31 Patients motivation Main mo-va-on for par-cipa-ng in a clinical trial (all groups together) Altruism- related motivation is the last one in the all groups together analysis but it is one of the most important reasons for patients decision. (90.4% % % % % % respectively)
32 Investigators motivation Which is the main mo-va-on for inves-gators decide to par-cipate in clinical trials? Provide the most innovative option for the patients, through the clinical trial Be updated with new medicines and medical procedures Social motivation Receive training and capacitation in clinical research Have an additional income Obligation in the institution where he/ she works Very important Moderately important Neutral Somewhat important Not important (all groups together)
33 Would you par-cipate again in a clinical trial? Would you recommend to others? 98% of research participants would accept participate in another clinical trial 98% of research participants would recommend to others the participation 98% Participariam Yes e recomendariam Não No
34 Fourth Domain: Opinions and impressions on the continuity of provision of study medication after trial
35 To whom? Who should receive the medica-on aser trial, if a benefit is proven? If proven more effec3ve than available op3ons, who should receive the study medica3on a?er trial end? EC MEMBERS (N=119) CLINICAL INVESTIGATORS (N=58) SPONSORS (N=24) RESEARCH PARTICIPANTS (N=53) Research pargcipants 26% 43% 33% 7% ParGcipants who benefit from the study medicagon and don t have other treatment opgon 23% 40% 50% 19% All people with the same disease in the country 35% 9% 0% 60% No one 7% 9% 8% 7% Some other group 8% 0% 8% 6%
36 To whom? Who should receive the medica-on aser trial, if a benefit is proven? 43 and 40% Clinical investigators 35% EC members 60% Research participants 50% Sponsors None All study participants Participants who benefit All with the disease Other group
37 How? How should the drug be furnished? How should be furnished the study medica3on a?er trial to the group iden3fied in the previous ques3on? EC MEMBERS (N=107) CLINICAL INVESTIGATORS (N=52) SPONSORS (N=22) RESEARCH PARTICIPANTS (N=44) Free of charge 55% 77% 64% 93% At a price established by government 20% 8% 0% 4% At the fabricagon cost 12% 4% 9% 0% At a price defined by the drug company 0% 2% 4% 2% Other 13% 10% 23% 0%
38 By whom? Who should be in charge of furnishing the drug aser trial? Who should be in charge of furnishing the drug a?er trial, before the regulatory approval in the country? EC MEMBERS (N=109) CLINICAL INVESTIGATORS (N=53) SPONSORS (N=22) RESEARCH PARTICIPANTS (NA) Sponsor (drug company) 64% 94% 68% NA Research insgtugon 8% 2% 4% NA Government 17% 4% 14% NA Other 10% 0% 14% NA (NA: not applicable, as this question was not applied to research participants)
39 How long? For how long.. For how long should the medica3on be furnished to the subjects? EC MEMBERS (N=124) CLINICAL INVESTIGATORS (N=58) SPONSORS (N=24) RESEARCH PARTICIPANTS (N=54) For the period defined in protocol and informed consent 17% 28% 4% 7% While the subjects benefit from the treatment 49% 38% 18% 29% While the researcher/physician believes appropriate 24% 24% 59% 31% Up to having the medicine available in the country or in the public system 41% 51% 73% 31% For all life 8% 2% 0% 51% Other 7% 7% 4% 2% (In this question, more than one alternative could be chosen.)
40 For how long? For a period defined in the protocol and/or in the IC While the participant keeps the benefit While the investigator judges as adequate Up to be available in the country and/or public sector For all life Other Clinical Investigators Ethics Committees Research Participants Sponsors
41 Benefit x Risks Thinking in the benefit but also in the safety of pa-ents (risks of an inves-ga-onal drug are not irrelevant), which would be the best op-on for the con-nuity of the treatment? Clin Invest (n=52) EC (n=116) Sponsors (n=22) All together Study medication 57.7% 28.3% % Treatment already available 28.8% 55.7% 81.8% 51.1% Other 13.5% 16% 18.2% 15.6%
42 Access? What do you understand by access? Clin Invest EC Sponsors (n=55) (n=115) (n=24) All together Furnished by the sponsor Made available after regulatory approval 67.3% 78.3% 25% 68.6% 25.5% 16.5% 54.2% 23.7% Other 7.3% 5.2% 20.8% 7.7% Furnished by the sponsor Made available after regulatory approval Clin Invest EC Sponsor Other
43 Beneficial? Is clinical trial conduc-on in Brazil beneficial or not?
44 Differences Differences between DM and HIV clinical inves-gators 38 investigators DM and 20 HIV/AIDS. (Only questions where significant difference was observed) The info regarding to how to obtain the study medication after trial The medicine should be kept while benefit exists Is better furnished by the HIV investigators than DM investigators. Is more mentioned by HIV investigators than DM investigators. Understanding access HIV investigators: furnished by the sponsor DM investigators: be available in the country after regulatory approval
45 Differences Differences between DM and HIV research par-cipants 14 patients DM and 40 HIV/AIDS. (Only questions where significant difference was observed) Free supply after trial? HIV patients: 100% free; DM patients: 78% free Study medication should be given while considered adequate by the investigator Is beneficial to have clinical trials in Brazil? More important for DM patients than HIV patients HIV patients: more beneficial (100% very beneficial) than DM patients (78% very beneficial)
46 - Selection method of patients - Only two diseases included Pioneer study: Conclusion - a chronic disease, besides HIV/AIDS, Limitations: - sponsors included, - developing country. - Population restrict to web users - Population restrict to Brazil - Small sample of patients - Assessment of what they think but not what they do. The solution is not simple nor unique Each research should have its evaluation as Each disease has its peculiarities and Each population, its needs. Thank you!
Tópico: Epidemiologia no planejamento e gestão de serviços de saúde CO-AUTHOR ASSESSMENT AS AN INDICATOR OF NATIONAL AND INTERNATIONAL COOPERATION & Moisés Goldbaum Sonia Mansoldo Dainesi, MD, MBA PhD
More informationNATIONAL HEALTH COUNCIL RESOLUTION Nº 251, DATED 7 AUGUST 1997
NATIONAL HEALTH COUNCIL RESOLUTION Nº 251, DATED 7 AUGUST 1997 Plenary of the National Health Council in its 15 th Special Meeting, held on 5 August 1997, in the exercise of its competencies, as set forth
More informationThe use of alcohol and drugs and HIV treatment compliance in Brazil
The use of alcohol and drugs and HIV treatment compliance in Brazil André Malbergier, MD, PhD Hospital das Clínicas Medical School University of São Paulo Brasil The Casa da AIDS offers specialized integral
More informationProvider Communica/on Interven/on at a Federally Qualified Health Center- based Farmers' Market: Implica/ons for Implementa/on Science
Provider Communica/on Interven/on at a Federally Qualified Health Center- based Farmers' Market: Implica/ons for Implementa/on Science Daniela B. Friedman, MSc, PhD Associate Professor, Department of Health
More informationThe EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2012) Sweden
The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe Sweden Question 1: What laws or regulations apply to an application for conducting a clinical trial in Sweden?
More informationQuality Management in Clinical Trials
CLINICAL CASE STUDY SERIES Quality Management in Clinical Trials Clinical trials are conducted to collect the data necessary to provide information for academia, industry, and regulators to make decisions
More informationGuidelines for preparing Standard Operating Procedures (SOP) for Institutional Ethics Committee for Human Research
Guidelines for preparing Standard Operating Procedures (SOP) for Institutional Ethics Committee for Human Research 1. Objective: The objective of this SOP is to contribute to the effective functioning
More informationCommunity-based Advocacy in the Criminal Justice System PRESENTED BY: KELLY DIXON, J.D. & EMILY TOFTE NESTAVAL, MSW ROCKY MOUNTAIN VICTIM LAW CENTER
Community-based Advocacy in the Criminal Justice System PRESENTED BY: KELLY DIXON, J.D. & EMILY TOFTE NESTAVAL, MSW ROCKY MOUNTAIN VICTIM LAW CENTER Mission: Transforming the criminal jus5ce system to
More informationand Regulatory Aspects
Good Clinical Practice and Regulatory Aspects Nora Espiritu MD, MPh, PhD (c) Former Executive Director of Research and Technology Transfer. Peruvian National Institute t of Health. Member of the Ethics
More informationPatient Inclusion in the Clinical Trial Process at Novartis Working to Make it Reality
Patient Inclusion in the Clinical Trial Process at Novartis Working to Make it Reality Therese Johnsen, Clinical Trial Intelligence Manager 8 June 2015, London Transparent, Patient Focused Drug Development
More informationQuestionnaire: Use of placebo-medication for treating depression. 1. Explanation about the Placebo Treatment for Depression
Questionnaire: Use of placebo-medication for treating depression We are conducting a research study aimed at examining the position of the subjects towards different treatment options for depression. In
More informationMedicine is an ever-changing field. Have we been taught about bioethics???
Medicine is an ever-changing field Undergraduate medical education focuses on clinical skills - diagnosis and treatment of diseases Bioethics too is an ever-changing field Have we been taught about bioethics???
More informationJoint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases 1 Updated November 10, 2009
Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases 1 Updated November 10, 2009 The innovative pharmaceutical industry 2 is committed to the transparency
More informationSubstance Abuse Services (Outpatient)
RYAN WHITE PART B PEER REVIEW 2009-2010 Virginia Department of Health Division of Disease Prevention HIV Care Services Chart Review Substance Abuse Services (Outpatient) ID# 1. Is there referral in the
More informationCenterWatch. volunteering. clinical trial. for a. www.centerwatch.com
volunteering for a clinical trial www.centerwatch.com :: about this pamphlet This pamphlet provides an overview of the clinical trials process and answers frequently asked questions that many potential
More informationHistory and Principles of Good Clinical Practice
History and Principles of Good Clinical Practice Cristina E. Torres, Ph.D. Social Science Professor, UPM-NIH FERCAP Coordinator ICH: International Conference on Harmonization GCP: Good Clinical Practices
More informationTHE IMPACT OF USING BLOOD SUGAR HOME MONITORING DEVICE TO CONTROL BLOOD SUGAR LEVEL IN DIABETIC PATIENTS
THE IMPACT OF USING BLOOD SUGAR HOME MONITORING DEVICE TO CONTROL BLOOD SUGAR LEVEL IN DIABETIC PATIENTS Alshammari S., *Al-Jameel N., Al-Johani H, Al-Qahtani A., Al-Hakbani A., Khan A. and Alfaraj S.
More informationStudy Participant Experiences
2013 Perceptions & Insights Study Report on Study Participant Experiences Regulatory agencies, ethical review committees, investigative sites, contract research organizations, and clinical research sponsors
More informationJoão Silva de Mendonça, MD, PhD Infectious Diseases Service Hospital do Servidor Público Estadual São Paulo - Brazil
Brazilian Ministry of Health, Brazilian Society of Hepatology PAHO, Viral Hepatitis Prevention Board PART III SESSION 9 Prevention and control of Viral Hepatitis in Brazil HEPATITIS IN SPECIAL RISK GROUPS/
More informationTAKING PART IN CANCER TREATMENT RESEARCH STUDIES
For more infomation about Cancer Clinical Trials at Upstate Cancer Center please call Upstate Connect 1.800.464.8668 TAKING PART IN CANCER TREATMENT RESEARCH STUDIES Information provided by: National Cancer
More informationEmergence of Compassionate Use programmes
Emergence of Compassionate Use programmes Rosanna Melchior, PharmD, MS IDRAC, Thomson Scientific Overview What is compassionate use (CU) Overview of CU in Europe Authorities and Sponsors Roles and Responsibilities
More informationI. INTRODUCTION DEFINITIONS AND GENERAL PRINCIPLE
Final: Approved by Partners Professional and Institutional Conduct Committee 8/11/04 Policy on Transfers to Third Parties Of Tissues, Other Specimens, and Data Obtained by Partners-Affiliated Providers
More informationClaim of Exemption Form Page 1 of 6
Claim of Exemption Form Page 1 of 6 Principal Investigator: Phone: Project or Protocol Title: Contact Person: Address: Phone: Fax: E-mail: Copy of Principal Investigator s CV attached SPONSOR / FUNDING
More informationClassifying Adverse Events From Clinical Trials
Classifying Adverse Events From Clinical Trials Bernard LaSalle, Richard Bradshaw University of Utah, Biomedical Informatics, Salt Lake City, UT USA bernie.lasalle@hsc.utah.edu Abstract The use of adverse
More informationNOW!! Registry and BioBank Services for! Your Organization/Company/Clinic/Project!
NOW!! Registry and BioBank Services for! Your Organization/Company/Clinic/Project! What Does Genetic Alliance Registry and BioBank Offer?! Flexible, customizable, registry and biobank options One-on-one
More informationExcessive alcohol consumption increases the likelihood of accidental injury. This
Abstract Excessive alcohol consumption increases the likelihood of accidental injury. This pilot study reports on the prevalence of hazardous drinkers presenting to a Minor Injuries Unit. The proportion
More informationRN NCLEX Pass Rates TBD. National 3 year mean (2012-2014) Program Completion Rates. Semester Admitted and enrolled in first nursing class
RN NCLEX Pass Rates Southeast Technical Institute RN Program NCLEX Pass Rates Compared to State and National NCLEX Pass Rates 2012 2013 2014 Southeast Technical Institute RN Program 92.5% 80% Annual Pass
More informationKennedy Krieger Institute. Policy and Procedure for Research Involving Nursing Resources. April 2011
Kennedy Krieger Institute Policy and Procedure for Research Involving Nursing Resources April 2011 Policy: Human research projects conducted within the Kennedy Krieger Institute (KKI) that require the
More informationNational Cancer Institute
National Cancer Institute Taking Part in Cancer Treatment Research Studies U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Taking Part in Cancer Treatment Research Studies If
More informationPa#ent Involvement in Clinical Research In Rela#onship with Biobanking BBMRI 15 December 2009
Pa#ent Involvement in Clinical Research In Rela#onship with Biobanking BBMRI 15 December 2009 Cor Oosterwijk Project Coordinator Pa;entPartner Dutch Gene;c Alliance VSOP European Gene;c Alliances Network
More informationParis, 15 June 2013 Response to a public consultation
Paris, 15 June 2013 Response to a public consultation Revision of the World Medical Association Helsinki Declaration: - transparency of clinical trial results must be enhanced (articles 23, 24 & 26) -
More informationRole of IRB/IEC in GCP. Benjamin Kuo, MD, Dr.PH, CIP.
Role of IRB/IEC in GCP Benjamin Kuo, MD, Dr.PH, CIP. Institutional Review Board (IRB) An independent body constituted of medical, scientific and non scientific members Responsible for ensuring protection
More informationOffice of Clinical Research (OCR)
Office of Clinical Research (OCR) Your Partner in the Clinical Research Process h3p://bsdocr.bsd.uchicago.edu Phone: 834-1238 Susan L. Cohn, MD Dean for Clinical Research Professor of Pediatrics OCR Created
More informationNew Trends In the Brazilian Healthcare Market. Rafael Vasconcellos,MD UHG
New Trends In the Brazilian Healthcare Market Rafael Vasconcellos,MD UHG Summary Overview Brazilian Healthcare Market Numbers Public System Private System Interaction Between Public X Private Innovations
More informationInformation Sheet Guidance for Sponsors, Clinical Investigators, and IRBs
Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs Frequently Asked Questions Statement of Investigator (Form FDA 1572) U.S. Department of Health and Human Services Food and Drug
More informationPediatric Trials Network. Danny Benjamin MD PhD Professor of Pediatrics Duke University www.dcri.org/about-us/conflict-of-interest
Pediatric Trials Network Danny Benjamin MD PhD Professor of Pediatrics Duke University www.dcri.org/about-us/conflict-of-interest Pediatric Drug Development 1998: essentially no trials Mandate (Pediatric
More informationManaging & Validating Research Data
Research Management Standard Operating Procedure ISOP-H02 VERSION / REVISION: 2.0 EFFECTIVE DATE: 01 03 12 REVIEW DATE: 01 03 14 AUTHOR(S): CONTROLLER(S): APPROVED BY: Information Officer; NBT Clinical
More informationResearch on Research: Learning about Phase 1 Trials
CLINICAL CASE STUDY SERIES Research on Research: Learning about Phase 1 Trials Phases of clinical trial investigation are described in some detail in the Code of Federal Regulations. Phase 1 is described
More informationOverview of CDISC Implementation at PMDA. Yuki Ando Senior Scientist for Biostatistics Pharmaceuticals and Medical Devices Agency (PMDA)
Overview of CDISC Implementation at PMDA Yuki Ando Senior Scientist for Biostatistics Pharmaceuticals and Medical Devices Agency (PMDA) CDISC 2012 Outline Introduction Update of PMDA activity CDISC implementation
More informationJob Profile Clinical Research Associate III (CRA)
PART 1 - PROFILE You are an experienced CRA with a strong background in Clinical Research who is passionate about drug development and are seeking a challenging and rewarding career in a quality focussed
More informationAccountable Care Organizations: Implications for CHCs Serving AA&NHOPIs
Accountable Care Organizations: Implications for CHCs Serving AA&NHOPIs Practice Transformation Webinar Series Webinar 4 April 29, 2015 Moderator: Nina Agbayani, Director of Programs About AAPCHO National
More informationYour Next 7 days EXECUTIVE SUPPORT TEAM MONDAY- 5AM PREM ERUVBETINE, DEXTER LAM, ALEX EAKINS & WILLIAM KATZ
Your Next 7 days EXECUTIVE SUPPORT TEAM MONDAY- 5AM PREM ERUVBETINE, DEXTER LAM, ALEX EAKINS & WILLIAM KATZ What are ALL the issues A) Staff resigna.on inappropriate behavior (later) B) Third quarter results
More informationUse of Observa,onal Data to Make Causal Inferences About Treatment Decisions in Mul,ple Sclerosis. Brian Healy, PhD
Use of Observa,onal Data to Make Causal Inferences About Treatment Decisions in Mul,ple Sclerosis Brian Healy, PhD Disclosures n I receive research support from Merck Serono and Novar,s Outline n Background
More informationYOUR GATEWAY TO. EXPERIENCE, quality & FLEXIBILITy
YOUR GATEWAY TO EXPERIENCE, quality & FLEXIBILITy DATA MANAGEMENT SERVICES The quality of your data defi ne the success of your trial, therefore proper handling of data is fundamental. Our Data Management
More informationClinical Trials at PMH
Clinical Trials at PMH What You Need To Know UHN Patient Education Improving Health Through Education A Guide for Patients, Their Families and Friends in the PMH Cancer Program This information is to be
More informationHow to Run Clinical Trials in Private Practice
How to Run Clinical Trials in Private Practice Thomas M. Siler, MD Midwest Chest Consultants, PC Saint Charles, MO DISCLOSURE Dr. Siler has received research grants from GlaxoSmithKline, Forest, Boehringer
More informationEMERGING MARKETS: CLIMATE CHANGE IN LATIN AMERICA MAKES FOR SUCCESSFUL CLINICAL TRIALS
EMERGING MARKETS: CLIMATE CHANGE IN LATIN AMERICA MAKES FOR SUCCESSFUL CLINICAL TRIALS The change in local regulatory guidelines ensuring faster project start-up, the ability to run trials six months out
More informationRESEARCH INVOLVING HUMAN SUBJECTS
RESEARCH INVOLVING HUMAN SUBJECTS GUIDELINES FOR IRBS PART A: INTRODUCTION AND CURRENT FRAMEWORK SECTION I: INTRODUCTION 1. Introduction About these Guidelines 1.1. The Bioethics Advisory Committee (BAC)
More informationClinical Research in Mauritius
BOARD OF INVESTMENT Clinical Research in Mauritius This document provides an informative summary of the procedure to apply for a clinical research protocol in Mauritius. Contents INTRODUCTION... 2 I. APPLICATION
More informationCERTIFICATE IN CLINICAL TRIAL MANAGEMENT
Temple University - School of Pharmacy 425 Commerce Drive, Suite 175 Fort Washington, PA 19034-2713 Phone: 267.468.8560 Fax: 267.468.8565 CERTIFICATE IN CLINICAL TRIAL MANAGEMENT Designed for Pharmaceutical
More informationPHARMACY AND POISONS ORDINANCE (Cap. 138) APPLICATION FOR A CLINICAL TRIAL/MEDICINAL TEST CERTIFICATE
PHARMACY AND POISONS ORDINANCE (Cap. 138) APPLICATION FOR A CLINICAL TRIAL/MEDICINAL TEST CERTIFICATE PART A: TRIAL INFORMATION A1. Title of Clinical Trial (as stated in proposed Protocol) Protocol No.
More informationRegulatory Considerations for Conducting Clinical Trials In India
Regulatory Considerations for Conducting Clinical Trials In India By Mukesh Kumar, PhD & Surinder Kher, MD In the last few years, there has been increasing interest in the pharmaceutical industry in outsourcing
More informationInfluence, Information Overload, and Information Technology in HealthCare.
Influence, Information Overload, and Information Technology in HealthCare. Inspiration: a clinical trial of an IT based decision support technology The IT system constructed a digital electronic medical
More informationNeeds, Providing Solutions
Identifying Needs, Providing Solutions 1 I n d u s t r y The growth of medical research and the countless innovations coming from the pharmaceutical, biotechnology and medical device industry, has improved
More informationPrincipal Investigator and Sub Investigator Responsibilities
Principal Investigator and Sub Investigator Responsibilities I. Purpose To define the roles and responsibilities of Principal Investigators conducting research at GRU. II. Definition The term Principal
More informationIndustry Experience in Clinical Trials Management. Catherine Lee Area Head Clinical Operations Asia Pfizer Inc 20 May 2011 Brussels
Industry Experience in Clinical Trials Management Catherine Lee Area Head Clinical Operations Asia Pfizer Inc 20 May 2011 Brussels Stakeholders in clinical research Critical activities to ensure patient
More informationNational Poll: Clinical Research June 2013 Results of a New Public Opinion
National Poll: Clinical Research June 2013 Results of a New Public Opinion Poll National Poll on Clinical Research The National Poll on Clinical Research was conducted online in May 2013 by Zogby Analytics
More informationImpact of Breast Cancer Genetic Testing on Insurance Issues
Impact of Breast Cancer Genetic Testing on Insurance Issues Prepared by the Health Research Unit September 1999 Introduction The discoveries of BRCA1 and BRCA2, two cancer-susceptibility genes, raise serious
More informationPlease find below some views on the issues raised by the EMA Senior Medical Officer's Reflections on the legal basis for EMA/CHMP opinions.
Jacques Ropers Afssaps Pierre Demolis Afssaps (French CHMP Member) Philippe Lechat Afssaps (French Alternate CHMP Member) Dear Colleagues, Please find below some views on the issues raised by the EMA Senior
More informationPa"ent Reported Outcomes Useful for Whom? Industry s Perspec/ve. Pri/ Jhingran, Ph.D. GlaxoSmithKline
Pa"ent Reported Outcomes Useful for Whom? Industry s Perspec/ve Pri/ Jhingran, Ph.D. GlaxoSmithKline AGENDA Why PROs? Applica0ons of PROs in Drug Development US Healthcare Reform Enhanced Value of PROs
More information298.015) UC 6:30 8:20 PM
Course Description: This course is an in depth review of the history, authorizing statute and regulatory authority of US FDA and the influence and impact of FDA on science and health policy. Drug development,
More informationOutcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital
Mahidol University Journal of Pharmaceutical Sciences 008; 35(14): 81. Original Article Outcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital
More informationClinical trials regulation
Clinical trials regulation The Proposal for a Regulation of the European Parliament and of the Council on Clinical Trials on Medicinal Products for Human Use and Repealing Directive 2001/20/EC an update
More informationPROCEDURE FOR PREPARING GCP INSPECTIONS REQUESTED BY THE EMEA. GCP Inspectors Working Group
European Medicines Agency Inspections London, 20 September 2007 EMEA/INS/GCP/197228/2005 Procedure no.: INS/GCP/2 PROCEDURE FOR PREPARING GCP INSPECTIONS REQUESTED BY THE EMEA GCP Inspectors Working Group
More informationDetermining who the investigators are and who the principal investigator is:
Responsibilities of the IRBs of the Health System and University for Research Conducted by Investigators from a Combination of the Following Institutions: the Health System, University, and Medical School
More informationInformation about research
Information about research Welcome to Papworth Hospital a focus on research As a specialist centre we pride ourselves on the quality of care that we provide for our patients. Knowledge in health care
More informationObtaining IRB approval for multi-center research: challenges and recommendations
Obtaining IRB approval for multi-center research: challenges and recommendations Keith Marsolo, PhD Assistant Professor Division of Biomedical Informatics Cincinnati Children s Hospital Medical Center
More informationDepartment of Construction
Department of Construction Program Quality Assessment Plan I. Description of Program s Assessment Procedures and Process The program quality assessment plan of the Department of Construction identifies
More information11. Extension Potential Financial Benefits
11. Extension Potential Financial Benefits Estimating the financial value of using electronic health records (EHR) for clinical research is fraught with difficulties for a number of reasons, some of which
More informationGlobalization of Clinical Trials Promise and Reality
Globalization of Clinical Trials Promise and Reality Zvi Ladin, Ph.D. Boston MedTech Advisors www.bmtadvisors.com November 2008 1 Outline Ethical principles Historical perspective Registration requirements
More informationPOLICY. Title: NIAID POLICY ON DATA AND SAFETY MONITORING BOARD (DSMB) OPERATIONS
POLICY Date: September 4, 2014 NIAID Bethesda, MD USA Page 1 of 11 Release Date: October 14, 2014 Effective Date: December 11, 2014 Title: NIAID POLICY ON DATA AND SAFETY MONITORING BOARD (DSMB) APPROVAL
More informationSharon H. Johnson, BS, MS 123 Main Street Capital City, VA 00000 Phone: 434-555-1234 Email: shjohnson@email.com
SAMPLE CRA CV Sharon H. Johnson, BS, MS 123 Main Street Capital City, VA 00000 Phone: 434-555-1234 Email: shjohnson@email.com Education: Masters of Science, Healthcare Administration, Capital City University,
More informationEXHIBIT COORDINATING PROVISIONS-STATE/FEDERAL LAW, ACCREDITATION STANDARDS AND GEOGRAPHIC EXCEPTIONS MARYLAND
EXHIBIT COORDINATING PROVISIONS-STATE/FEDERAL LAW, ACCREDITATION STANDARDS AND GEOGRAPHIC EXCEPTIONS MARYLAND I. INTRODUCTION: Scope. To the extent of any conflict between the Agreement and this State
More informationSchool of Pharmacy TEMPLE UNIVERSITY
School of Pharmacy TEMPLE UNIVERSITY Regulatory Affairs and Quality Assurance Graduate Program Te mple Unive rsity School of Pharmacy Re gulatory Affairs and Quality Assurance Graduate Program 4 25 Comme
More informationInfoset builds software and services to advantage business operations and improve patient s life
Infoset builds software and services to advantage business operations and improve patient s life Clinical Data Management ecrf & EDC Patient Support Programs Medication Adherence Mobile e-health Big Data
More informationGood Clinical Practice 101: An Introduction
Good Clinical Practice 101: An Introduction Presented by: Lester Jao Lacorte, MD Medical Officer Commissioner s Fellow Division of Bioresearch Monitoring Office of Compliance Center for Devices and Radiological
More informationGuidance for Industry
Guidance for Industry Expanded Access to Investigational Drugs for Treatment Use Qs & As DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
More informationRevisions on the Declaration of Helsinki
Revisions on the Declaration of Helsinki Prof. J. Mfutso-Bengo, PhD Center of Bioethics (CEBESA) University of Malawi College of Medicine Cape Town South Africa December 2012 www.medcol.mw Joseph-matthew@gmx.net
More informationSeptember 20, 2012. Kelly Willenberg, MBA, BSN, CHC, CHRC. Kelly Willenberg, LLC
September 20, 2012 Kelly Willenberg, MBA, BSN, CHC, CHRC 1 1 Understand the importance of research billing compliance and how that impacts the hospital and your practice Understand how billing can advance
More informationFeasibility study to evaluate the usability of the newly developed health care management software ecare*seniors in primary care practices.
Trial Description Title Patient-centered health care management in primary care: feasibility study evaluating the usability of the computer-based information system ecare*seniors for the individual health
More informationNEW YORK STATE EXTERNAL APPEAL
NEW YORK STATE EXTERNAL APPEAL You have the right to appeal to the Department of Financial Services (DFS) when your insurer or HMO denies health care services as not medically necessary, experimental/investigational
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON DATA MONITORING COMMITTEES
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 27 July 2005 Doc. Ref. EMEA/CHMP/EWP/5872/03 Corr COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE
More informationWHAT ARE THE SPECIFIC DIFFERENCES BETWEEN VERSION 5.5 AND VERSION 5.6 OF THE RESEARCH ETHICS COMMITTEE STANDARD APPLICATION FORM?
Application Form Cover Sheet - Addition of Application Version No. in Version 5.6 - Addition of Application Date in Version 5.6 - Remove Principal Investigator (deletion) - Remove Applicant s Signature
More informationGuidance for Industry
Guidance for Industry IND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer U.S. Department of Health and Human Services Food and Drug Administration Center
More informationTemple University - School of Pharmacy 425 Commerce Drive, Suite 175 Fort Washington, PA 19034. Phone: 267.468.8560 Fax: 267.468.
Temple University - School of Pharmacy 425 Commerce Drive, Suite 175 Fort Washington, PA 19034 Phone: 267.468.8560 Fax: 267.468.8565 POST-MASTER S CERTIFICATE in CLINICAL TRIAL MANAGMENT Designed for Pharmaceutical
More informationWORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI
WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI Ethical Principles for Medical Research Involving Human Subjects Adopted by the 18 th WMA General Assembly Helsinki, Finland, June 1964 and amended by
More informationNurse Researcher or Clinical Research Nurse: Understanding the Difference
Nurse Researcher or Clinical Research Nurse: Understanding the Difference Claudia D. Smith, PhD, RN, NE-BC Director, Nursing Research St. Luke s Medical Center An Alternate Title for the Presentation:
More informationGuidance for Sponsors, Investigators, and Institutional Review Boards. Questions and Answers on Informed Consent Elements, 21 CFR 50.
Guidance for Sponsors, Investigators, and Institutional Review Boards Questions and Answers on Informed Consent Elements, 21 CFR 50.25(c) (Small Entity Compliance Guide) U.S. Department of Health and Human
More informationWHOQOL-HIV Instrument
WHO/MSD/MER/02.1 English only Distr.: General WHOQOL-HIV Instrument Users Manual Scoring and Coding for the WHOQOL-HIV Instruments MENTAL HEALTH: EVIDENCE AND RESEARCH DEPARTMENT OF MENTAL HEALTH AND SUBSTANCE
More informationMarket Research as an agent of change in pharmerging Asia
Market Research as an agent of change in pharmerging Asia Agenda The challenge The solution The case study Conclusion Agenda The challenge The solution The case study Conclusion The challenge Huge expectation
More informationLI, Huafang MD., Ph.D. Shanghai Mental Health Center Shanghai Jiao Tong University School of Medicine, Shanghai, China
Late Clinical Trials in China LI, Huafang MD., Ph.D. Shanghai Mental Health Center Shanghai Jiao Tong University School of Medicine, Shanghai, China Biography Huafang LI, M.D., Ph.D., Chief-Psychiatrist,
More informationThe Swiss National Clinical Trials Portal a new database on clinical trials?
The Swiss National Clinical Trials Portal a new database on clinical trials? Meet and Greet for Swiss Biomedical Librarians 8 September 2014, Hotel Kreuz, Berne Hosted by the Biomedical Library Committee
More informationLaurie Shaker-Irwin, Ph.D., M.S. Co-Leader, Regulatory Knowledge and Research Ethics UCLA Clinical and Translational Science Institute
Laurie Shaker-Irwin, Ph.D., M.S. Co-Leader, Regulatory Knowledge and Research Ethics UCLA Clinical and Translational Science Institute Understand the protocol completely Recognize institutional polices
More informationClinical Data Management (Process and practical guide) Nguyen Thi My Huong, MD. PhD WHO/RHR/SIS
Clinical Data Management (Process and practical guide) Nguyen Thi My Huong, MD. PhD WHO/RHR/SIS Training Course in Sexual and Reproductive Health Research Geneva 2013 OUTLINE Overview of Clinical Data
More informationTo IRB, or Not to IRB? That Is the Question!
To IRB, or Not to IRB? That Is the Question! A presentation by Mary Sapp, Ph.D. Assistant Vice President, Planning & Institutional Research University of Miami and Thomas K. Martin, Ph.D. Associate Vice
More informationAllgemeine Rahmenbedingungen für die Entwicklung und Zulassung von Orphan Medicinal Products
Allgemeine Rahmenbedingungen für die Entwicklung und Zulassung von Orphan Medicinal Products PMS-Workshop Arzneimitteltherapie seltener Krankheiten Herausforderungen und Chancen Berlin-Brandenburgische
More informationBiotech Concerto #3. European Clinical Trial Environment
Biotech Concerto #3 European Clinical Trial Environment December 2008 Index EU Directive EU Approval System European Authority: EMEA The Guidance Documents Route Map Challenges EMEA Organization Chart
More informationElectronic Submission of Regulatory Information, and Creating an Electronic Platform for Enhanced Information Management
Written Notice of Participation by the Clinical Data Interchange Standards Consortium (CDISC) and Written Statement for Discussion Topics to be Addressed In the FDA Public Hearing: Electronic Submission
More informationRD SOP17 Research data management and security
RD SOP17 Research data management and security Version Number: V2 Name of originator/author: Dr Andy Mee, R&I Manager Name of responsible committee: R&I Committee Name of executive lead: Medical Director
More information